0001279569-19-000644.txt : 20190320 0001279569-19-000644.hdr.sgml : 20190320 20190320141106 ACCESSION NUMBER: 0001279569-19-000644 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20190320 FILED AS OF DATE: 20190320 DATE AS OF CHANGE: 20190320 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Correvio Pharma Corp. CENTRAL INDEX KEY: 0001036141 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: A1 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-29338 FILM NUMBER: 19694386 BUSINESS ADDRESS: STREET 1: 6TH FLOOR STREET 2: 1441 CREEKSIDE DRIVE CITY: VANCOUVER STATE: A1 ZIP: V6J 4S7 BUSINESS PHONE: 1-604-677-6905 MAIL ADDRESS: STREET 1: 6TH FLOOR STREET 2: 1441 CREEKSIDE DRIVE CITY: VANCOUVER STATE: A1 ZIP: V6J 4S7 FORMER COMPANY: FORMER CONFORMED NAME: Cardiome Pharma Corp DATE OF NAME CHANGE: 20040625 FORMER COMPANY: FORMER CONFORMED NAME: CARDIOME PHARMA CORP DATE OF NAME CHANGE: 20000407 6-K 1 correvio6k.htm FORM 6-K

 

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

Report of Foreign Private Issuer

Pursuant to Rule 13A-16 or 15d-16 of

The Securities Exchange Act of 1934

 

For the month of March 2019

 

COMMISSION FILE Number. 000-29338

 

CORREVIO PHARMA CORP.

 

(Translation of registrant’s name into English)

 

1441 Creekside Drive, 6th floor

Vancouver, British Columbia, V6J 4S7, CANADA

 

(Address of principal executive offices)

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F

 

Form 20-F ☐ Form 40-F ☒

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

  

 

 

 
 

 

 

DOCUMENTS INCLUDED AS PART OF THIS REPORT

 

Exhibit   Description
     
99.1   News Release dated March 20, 2019

  

 

 

 

 

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  CORREVIO PHARMA CORP.
  (Registrant)
     
Date: March 20, 2019 By: /s/ Justin Renz
    Name: Justin Renz
    Title: President and Chief Financial Officer

 

 

 


 EX-99.1 2 ex991.htm NEWS RELEASE DATED MARCH 20, 2019

Exhibit 99.1

 

 

 

Correvio Announces Presentation Of Brinavess® Data At The American College Of Cardiology 2019 Annual Meeting

Data Will Also Be Presented at the Upcoming 23rd Israeli Congress for Emergency Medicine  

NASDAQ: CORV   TSX: CORV

VANCOUVER, March 20, 2019 /CNW/ - Correvio Pharma Corp. (NASDAQ: CORV) (TSX: CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, today announced the presentation of new Brinavess® (vernakalant hydrochloride, IV) data at the American College of Cardiology 2019 Annual Meeting taking place March 16-18, 2019, in New Orleans.  This poster presentation highlights reduced hospitalization in patients treated with Brinavess, Correvio's antiarrhythmic drug for the rapid conversion of recent onset atrial fibrillation (AF), from a clinical survey assessing patients with acute AF at the Hillel Yaffe Medical Center located in Hadera, Israel.

This presentation, titled "Intravenous Vernakalant for the Treatment of New-Onset Atrial Fibrillation in the Emergency Department," was given by Jameel Mohsen, MD, Hillel Yaffe Medical Center. In this survey, a total of 101 patients with recent onset AF were treated with Brinavess in the emergency department.  The data demonstrated that treatment with Brinavess had an overall conversion rate to sinus rhythm of 74% (75 out of 101 patients). Among the 75 patients who were successfully converted, 57 (76%) were converted to sinus rhythm after a single dose of Brinavess.  The remaining 18 patients (24%) converted after the second dose of Brinavess. The average time to conversion after one dose was 12.7 minutes, while the average combined time to conversion after a first and second dose was 21 minutes. Of the 75 patients who were converted, all (100%) were discharged home with normal sinus rhythm within 3-4 hours following admission, with no need for hospitalization.

"These data provide important, real-world clinical information on the use of Brinavess for the treatment of acute AF in the emergency room setting in Israel," said Carin Heringa, Correvio's Head of Medical Affairs. "In this study, normal heart rhythm was restored in 74% of patients, thereby avoiding electric cardioversion, its accompanying side effects and hospitalization. We continue to believe that Brinavess offers an important treatment alternative for patients with recent onset AF, and particularly for those who will benefit from pharmacologic cardioversion."

These data, along with other real-world data and topics, will also be presented at the upcoming 23rd Israeli Congress for Emergency Medicine taking place March 26, 2019 in Tel Aviv, Israel.  Details for the upcoming presentation are as follows:

Title: Improving Patient Discharge Rate from the  Emergency Department to the Community by Converting Recent Onset Atrial Fibrillation to Sinus
Presenter: Dr. Aziz Darawsha, Rambam Medical Center
Date and time: Tuesday, March 26, 2019; 12:50-13:10
Location: Dan Panorama Hotel, Hall B

About Atrial Fibrillation

Atrial Fibrillation (also known as AFib or AF) is a supraventricular tachyarrhythmia with uncoordinated atrial activation resulting in ineffective atrial contraction and if left untreated, structural and/or electrophysiological atrial tissue abnormalities.1 AF is a common cardiac rhythm disturbance that increases in prevalence with advancing age.1 According to the American Heart Association, estimates of the prevalence of AF in the U.S. ranged from 2.7 million to 6.1 million in 2010, and is expected to rise to between 5.6 million to 12 million in 2030.2

There are two strategies to manage AF, namely, rhythm- or rate-control. A rhythm-control strategy may be used in patients who are severely compromised, remain symptomatic despite adequate rate control, when adequate rate control is difficult to achieve, when long term rhythm control therapy is preferred, younger patient age, presence of tachycardia-mediated cardiomyopathy, and first episode of AF.1,3 Early intervention with a rhythm-control strategy to prevent progression of AF may be particularly beneficial to the AF patient.1

About Brinavess®

Brinavess® (vernakalant HCl, IV) is an antiarrhythmic drug that acts preferentially in the atria by prolonging atrial refractoriness and slowing impulse conduction in a rate-dependent fashion. Brinavess is approved for marketing in Europe, Canada and several other countries worldwide. In Europe, it is approved for the rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults: 1) for non-surgery patients: atrial fibrillation < 7 days duration; and 2) for post-cardiac surgery patients: atrial fibrillation <3 days duration. Vernakalant IV is not approved for use in the United States.

About Correvio Pharma Corp.

Correvio Pharma Corp. is a specialty pharmaceutical company focused on providing innovative, high-quality brands that meet the needs of acute care physicians and patients. With a commercial presence and distribution network covering over 60 countries worldwide, Correvio develops, acquires and commercializes brands for the in-hospital, acute care market segment. The Company's portfolio of approved and marketed brands includes: Xydalba™ (dalbavancin hydrochloride), for the treatment of acute bacterial skin and skin structure infections (ABSSSI); Zevtera®/Mabelio® (ceftobiprole medocaril sodium), a cephalosporin antibiotic for the treatment of community- and hospital-acquired pneumonia (CAP, HAP); Brinavess® (vernakalant IV) for the rapid conversion of recent onset atrial fibrillation to sinus rhythm; Aggrastat® (tirofiban hydrochloride) for the reduction of thrombotic cardiovascular events in patients with acute coronary syndrome, and Esmocard® and Esmocard Lyo® (esmolol hydrochloride), a short-acting betablocker used to control rapid heart rate in a number of cardiovascular indications. Correvio's pipeline of product candidates includes Trevyent®, a drug device combination that is designed to deliver treprostinil, the world's leading treatment for pulmonary arterial hypertension.

Correvio is traded on the NASDAQ Capital Market (CORV) and the Toronto Stock Exchange (CORV). For more information, please visit our web site www.correvio.com.

References

1.January CT et al. 2014 AHA/ACC /HRS guideline for the management of patients with atrial fibrillation. J AM Coll Cardiol. 2014;34:e1-e76.
2.Mozaffarian D et al. Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association. Circulation. 2016 Jan 26;133(4):e38-60.
3.Camm AJ et al. Guidelines for the management of atrial fibrillation, The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;31:2369-2429.

Forward-Looking Statement Disclaimer

Certain statements in this news release contain "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 or "forward-looking information" under applicable Canadian securities legislation (collectively, "forward-looking statements"). Forward-looking statements include statements that may relate to our plans, objectives, goals, strategies, future events, future revenue or performance, capital expenditures, financing needs and other information that may not be based on historical fact. Forward-looking statements can often be identified by the use of terminology such as "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect", "look forward to" and similar expressions. Forward-looking statements are necessarily based on estimates and assumptions made by us based on our experience and perception of historical trends, current conditions and expected future developments, as well as other factors we believe are appropriate.

These forward-looking statements may include, but are not limited to, any future rise in the prevalence of AF in the United States and any potential benefits of a rhythm-control strategy to prevent progression of AF.

By their very nature, forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. A detailed discussion of the risks and uncertainties facing Correvio are discussed in the annual report and detailed from time to time in our other filings with the Securities and Exchange Commission ("SEC") available at www.sec.gov and the Canadian securities regulatory authorities at www.sedar.com. In particular, we direct your attention to Correvio's Annual Report on Form 40-F for the year ended December 31, 2018. All of the risks and certainties disclosed in those filings are hereby incorporated by reference in their entirety into this news release.

While Correvio makes these forward-looking statements in good faith, given these risks, uncertainties and factors, you are cautioned not to place undue reliance on any forward-looking statements made in this press release. All forward-looking statements made herein are based on our current expectations and we undertake no obligation to revise or update such forward-looking statements to reflect subsequent events or circumstances, except as required by law. Investors are cautioned that forward-looking statements are not guarantees of future performance and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to their inherent uncertainty.

Correvio® and the Correvio Logo are the proprietary trademarks of Correvio Pharma Corp.
Aggrastat® and Brinavess® are trademarks owned by Correvio and its affiliates worldwide.
Xydalba™ is a trademark of Allergan Pharmaceuticals International Limited, and used under license.
Zevtera® and Mabelio® are trademarks owned by Basilea Pharmaceutica International Ltd., and used under license.
Esmocard® and Esmocard Lyo® are trademarks owned by Orpha-Devel Handels und Vertriebs GmbH, and used under license.
Trevyent® is a trademark of SteadyMed Ltd. and used under license.
All other trademarks are the property of their respective owners.

View original content:http://www.prnewswire.com/news-releases/correvio-announces-presentation-of-brinavess-data-at-the-american-college-of-cardiology-2019-annual-meeting-300815049.html

SOURCE Correvio Pharma Corp

 

View original content: http://www.newswire.ca/en/releases/archive/March2019/20/c3080.html

%CIK: 0001036141

For further information: Justin Renz, President & CFO, Correvio Pharma Corp., 604.677.6905 ext. 128, 800.330.9928, jrenz@correvio.com; Argot Partners, Michelle Carroll/Claudia Styslinger, 212.600.1902, michelle@argotpartners.com, claudia@argotpartners.com

CO: Correvio Pharma Corp

CNW 08:00e 20-MAR-19

 EX-99.1 3 ex991.pdf PRINTER-FRIENDLY VERSION begin 644 ex991.pdf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